| Status: Excluded due to NICE appraisal | |
Product meets AWMSG exclusion criteria due to NICE appraisal TA327: Dabigatran etexilate for the treatment and secondary prevention of deep vein thrombosis and/or pulmonary embolism |
|
Medicine details |
|
| Medicine name | dabigatran etexilate (Pradaxa®) |
| Formulation | 110 mg, 150 mg capsule |
| Reference number | 1400 |
| Indication | Treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), and prevention of recurrent DVT and PE in adults |
| Company | Boehringer Ingelheim Ltd |
| BNF chapter | Cardiovascular system |
| Assessment type | N/A |
| Status | Excluded due to NICE appraisal |
| Date of issue | 17/06/2014 |
| NICE guidance | |